Dimensional assessment of onset of action of antidepressants: A comparative study of moclobemide vs. clomipramine in depressed patients with blunted affect and psychomotor retardation

Psychiatry Research

Volumn 79, Issue 3, 1998, Pages 267-275

  Jouvent, Roland ^a   Le Houezec, Jacques ^a   Payan, Christine ^a   Mikkelsen, Hans ^a   Fermanian, Jacques ^b   Millet, V éronique ^c   Dufour, Henri ^d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c Produits Roche SA   (France)

^d DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

Author keywords

Clomipramine; Depression; Early onset; Moclobemide; Monoamine oxidase inhibitor; Negative symptoms

Indexed keywords

CLOMIPRAMINE; MOCLOBEMIDE;

ADULT; AGED; AGITATION; ANXIETY; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; RANDOMIZED CONTROLLED TRIAL; TREMOR; VERTIGO; VISUAL IMPAIRMENT; XEROSTOMIA;

ADULT; AFFECTIVE SYMPTOMS; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BENZAMIDES; CHI-SQUARE DISTRIBUTION; CLOMIPRAMINE; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOKINESIA; MALE; MIDDLE AGED; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0032514130     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1781(98)00046-8     Document Type: Article

References (27)

1. Abrams R., Taylor M.A. A rating scale for emotional blunting. American Journal of Psychiatry. 135:1978;226-229.
2. American Psychiatric Association, 1987. Diagnostic and Statistical Manual of Mental Disorders, 3rd ed., revised (DSM-III-R). American Psychiatric Association, Washington, DC.
3. Angst J., Stabl M. Efficacy of moclobemide in different patient groups: a meta-analysis of studies. Psychopharmacology. 106:1992;109-113.
4. Bungener C., Jouvent R., Derouesné C. Affective disturbances in Alzheimer's disease. Journal of the American Geriatric Society. 44:1996;1-6.
5. Carton S., Jouvent R., Bungener C., Widlöcher D. Mood dimensions and sensation seeking. Personality and Individual differences. 13:1992;843-849.
6. Colzi A., d'Agostini F., Cesura A.M., Da Prada M. Brain microdialysis in rats; a technique to reveal competition in vivo between endogenous dopamine and moclobemide, a RIMA antidepressant. Psychopharmacology. 106:1992;17-20.
7. Danish University Antidepressant Group (DUAG) Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. Journal of Affective Disorders. 28:1993;105-116.
8. Da Prada M., Zürcher G., Wüthrich I., Haefely W.E. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. Journal of Neural Transmission. 26(Suppl.):1988;31-56.
9. Dürrigl V., Hodoba D., Folnegovicz-Smalc V. Polygraphic characteristics of night sleep in depressed patients treated with moclobemide or imipramine. Neurologia. 37(Suppl. 1):1988;24.
10. Funke H.J., Moritz F., Hellern K., Malanowskui H. Moclobemide versus clomipramine in the treatment of depression: a single-centre study, Federal Republic of Germany. Acta Psychiatrica Scandinavica. 82(Suppl. 360):1990;46-47.
11. Guelfi J.D., Payan C., Fermanian J., Pédarriosse A.M., Manfredi R. Moclobemide versus clomipramine in endogenous depression. A double-blind randomized clinical trial. British Journal of Psychiatry. 160:1992;519-524.
12. Haefely W., Burkard W.P., Cesura A.M., Kettler R., Lorez H.P.et al. Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology. 106:1992;6-14.
13. Hindmarch I., Kerr J. Behavioral toxicity of antidepressants with particular reference to moclobemide. Psychopharmacology. 106:1992;49-55.
14. Jouvent R., Vindreau C., Montreuil M., Bungener C., Widlöcher D. La clinique polydimensionnelle de l'humeur dépressive. Nouvelle version de l'échelle EHD. Psychiatrie et Psychobiologie. 3:1988;245-253.
15. Koczkas C., Holm P., Karisson A. Moclobemide and clomipramine in endogenous depression: a randomized clinical trial. Acta Psychiatrica Scandinavica. 79:1989;523-529.
16. Larsen J.K., Holm P., Hoyer E., Mejlhede A., Mikkelsen P.L.et al. Moclobemide and clomipramine in reactive depression. A placebo-controlled randomized clinical trial. Acta Psychiatrica Scandinavica. 79:1989;530-536.
17. Larsen J.K., Gjerris A., Holm P. Moclobemide in depression: a randomized, multicentre trial against isocarboxazide and clomipramine emphasizing atypical depression. Acta Psychiatrica Scandinavica. 84:1991;564-570.
18. Larsen J.K., Holm P., Mikkelsen P.L. Moclobemide and clomipramine in the treatment of depression: a randomized clinical trial. Acta Psychiatrica Scandinavica. 70:1984;254-256.
19. Lecrubier Y., Guelfi J.D. Efficacy of reversible inhibitors of monoamine oxidase A in various forms of depression. Acta Psychiatrica Scandinavica. 360:1990;18-23.
20. Maj J., Przegalinski E., Mogllnicka E. Hypothesis concerning the mechanisms of action of antidepressant drugs. Reviews in Physiological and Biochemical Pharmacology. 100:1984;1-74.
21. Montgomery S.A., Åsberg M.A. A new depression scale designed to be sensitive to change. British Journal of Psychiatry. 134:1979;382-389.
22. Priest R.G., Schmid-Burgk W. Moclobemide in the treatment of depression. Reviews in Contemporary Pharmacotherapy. 5:1994;35-43.
23. Randrup A., Munkvad I., Fog R., Gerlach J., Molander L. et al., 1975. Mania depression and brain dopamine. In: Essmann, W.B., Valzelli, L. (Eds.), Current Developments in Psychopharmacology. Spectrum Publ., New York, pp. 205-248.
24. Stabl M., Bizière K., Schmid-Burgk W., Amrein R. Review of comparative clinical trials. Moclobemide vs. tricyclic antidepressants and vs. placebo in depressive states. Journal of Neural Transmission. 28(Suppl.):1989;77-89.
25. Tyrer P., Owen R.T., Cicchetti D.V. The Brief Scale for Anxiety: a subdivision of the Comprehensive Psychopathological Rating Scale. Journal of Neurology, Neurosurgery and Psychiatry. 47:1984;970-975.
26. Widlöcher, D., 1983. Retardation: a basic emotional response? In: Davis, J.M., Maas, J.W. (Eds.), The Affective Disorders. American Psychiatric Press, Washington DC.
27. Willner P. Dopamine and depression: a review of recent evidence. III. The effects of antidepressant treatments. Brain Research Review. 6:1983;237-246.